Start-Up Quarterly Statistics, Q3 2012
This article was originally published in Start Up
Executive Summary
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
You may also be interested in...
Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.
Aerpio Obtains $27M In Series A To Fund Pair Of Phase II Studies
The recently spun-out company raised money to fund two Phase II trials in hopes of garnering a partner for its diabetic macular edema drug.